on Partners Group (isin : CH0024608827)
Partners Group Exits Initial Investment in PCI Pharma Services
Partners Group has announced its exit from its initial investment in PCI Pharma Services, reaping significant returns for its clients. Since the acquisition in 2016, Partners Group's investments have transformed PCI from a regional packaging entity into a global contract manufacturing and development organization (CDMO).
A consortium, led by Bain Capital and Kohlberg & Company, will acquire a majority stake, while Partners Group will retain a minority stake to facilitate further growth. This strategy focuses on enhancing PCI's capabilities in drug development and manufacturing.
The investment aligns with increasing global pharmaceutical trends. Partners Group has played a key role in expanding PCI's services, which now span advanced drug delivery and biologics production, among others. Ropes & Gray LLP advised on this transaction.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Partners Group news